Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.66 |
| ▸ | FLT1 | P17948 | 2/20 | 0.66 |
| ▸ | TUBB4A | P04350 | 15/20 | 0.65 |
| ▸ | TUBB | P07437 | 15/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 15/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 15/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 15/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 15/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 15/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 15/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 15/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 15/20 | 0.65 |
| ▸ | TUBA1A | Q71U36 | 15/20 | 0.65 |
| ▸ | TUBA1C | Q9BQE3 | 15/20 | 0.65 |
| ▸ | TUBB6 | Q9BUF5 | 15/20 | 0.65 |
| ▸ | TUBB2B | Q9BVA1 | 15/20 | 0.65 |
| ▸ | TUBB1 | Q9H4B7 | 15/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181641 | 0.92 | TUBB4A (0.65) | KDRFLT1TUBB4ATUBBTUBA3C | |
| SCHEMBL4173414 | 0.91 | TUBB4A (0.69) | KDRFLT1TUBB4ATUBBTUBA3C | |
| SCHEMBL4176979 | 0.90 | TUBB4A (0.78) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4174278 | 0.90 | TUBB4A (0.82) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4174177 | 0.90 | TUBB4A (0.78) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4180954 | 0.84 | TUBB4A (0.70) | KDRFLT1TUBB4ATUBBTUBA3C | |
| SCHEMBL4166024 | 0.83 | TUBB4A (0.65) | KDRFLT1TUBB4ATUBBTUBA3C | |
| SCHEMBL4167666 | 0.82 | KDR (0.60) | KDRFLT1TUBB4ATUBBTUBA3C | |
| SCHEMBL4169660 | 0.79 | TUBB4A (1.00) | KDRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4177063 | 0.79 | TUBB4A (0.90) | KDRTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | KDR 3284/4885FLT1 3408/4885TUBB4A 777/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | KDR 3284/4885FLT1 3408/4885TUBB4A 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.